A Three-Part Phase 1 Study to Evaluate the Potential Drug-Drug Interactions Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel-Ethinyl Estradiol-Containing Oral Contraceptives, and Carbamazepine in Healthy Adult Participants

This study will investigate the potential drug interactions between vemircopan and metformin, rosuvastatin, levonorgestrel/ ethinyl estradiol (LNG/EE)-containing oral contraceptive(s) (OCs), and carbamazepine in healthy participants.

开始日期2024-01-17

申办/合作机构

Alexion Pharmaceuticals, Inc.

NCT05780645

/ Completed临床1期

A Two-Part Phase 1 Study to Evaluate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

The primary objectives of this study are to investigate the relative bioavailability and PK (Pharmacokinetic) profile of 2 ALXN2050 MR (Modified Release) formulations in comparison with the IR (Immediate Release) formulation.

开始日期2023-03-15

申办/合作机构

Alexion Pharmaceuticals, Inc.

NCT05578846

/ Completed临床1期

A Phase 1 Study to Assess the Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics in Healthy Adult Participants

This study will assess the Bioequivalence between 180 mg and 60 mg ALXN2050 Tablets and the Effect of Food on ALXN2050 Pharmacokinetics.

开始日期2022-10-13

申办/合作机构

Alexion Pharmaceuticals, Inc.

[+1]

100 项与维米克泮相关的临床结果

登录后查看更多信息

100 项与维米克泮相关的转化医学

登录后查看更多信息

100 项与维米克泮相关的专利（医药）

登录后查看更多信息

项与维米克泮相关的文献（医药）

2025-07-01·PHARMACEUTICAL RESEARCH

First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated Diseases

Article

作者: Boyer, David ; Thanassi, Jane ; Zhao, Yongsen ; Huang, Mingjun ; Podos, Steven D ; Gadhachanda, Venkat R ; Wiles, Jason A ; Wang, Lijuan ; Patel, Dhara

OBJECTIVE:

The goal of the study was to discover small molecular inhibitors of complement factor D (FD), an essential protease for activation of the alternative pathway (AP) of complement, that possess the characteristics for clinical investigation in complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH).

METHODS:

Compounds were synthesized and tested in vitro for potency, selectivity, and metabolic stability. The optimized compounds were subjected further to a panel of in vitro tests for primary and secondary pharmacology including inhibitory effects on FD, different complement pathways and disease models, as well as to pharmacokinetic and pharmacodynamic evaluations in animals.

RESULTS:

Following multiple rounds of optimization, danicopan and later vermicopan were chosen as candidates for clinical investigation. Both compounds demonstrated potent and selective inhibitory effects on FD and AP, suitable pharmacokinetic characteristics for oral dosing, and efficacy in PNH in vitro disease models. In addition to enhanced in vitro potency, vemircopan exhibited lower clearance and higher bioavailability in animal studies compared with danicopan.

CONCLUSION:

Preclinical evaluations of danicopan and vermicopan provided rationales to conduct clinical studies in complement-mediated diseases. Recently, danicopan was approved as an add-on therapy to the C5 inhibitors ravulizumab or eculizumab for the treatment of extravascular hemolysis in patients with PNH.

2025-01-01·AMERICAN JOURNAL OF HEMATOLOGY

Massive hemolysis in paroxysmal nocturnal hemoglobinuria after switching from proximal complement inhibitor to anti‐ C5 therapy: A lesson not to be forgotten

Letter

作者: Notaro, Rosario ; Frieri, Camilla ; Marano, Luana ; Sanseverino, Ada ; Urciuoli, Eleonora ; Nannelli, Caterina ; Risitano, Antonio M.

We report the unique circumstance of three PNH patients treated with the factor D inhibitor vemircopan as monotherapy within the clin. trial NCT04170023.The trial was unexpectedly terminated by the sponsor's decision, following an interim anal. claiming that vemircopan monotherapy "Did not appropriately control IVH; significantly increased rates of BTH and LDH excursions (LDH excursions is defined by LDH values >x2ULN) compared with ravulizumab".To minimize the risk of massive intravascular hemolysis, the switch to the standard-of-care ravulizumab was planned 2 wk before vemircopan discontinuation.Thus, vemircopan discontinuation only occurred after completing the ravulizumab loading phase, guaranteeing that ravulizumab was in its therapeutic range at time of vemircopan discontinuation.At baseline (last day of vemircopan treatment), Hb level was remarkable in all three patients, the lowest value was 11 g/dL in patient A because of iron deficiency secondary to hypermenorrhea. All patients had normal or slightly increased LDH, consistent with adequate control of intravascular hemolysis .Here, we show for the first time, that rebound hemolysis following the discontinuation of effective treatment with proximal complement inhibitors is a major clin. risk that cannot be fully prevented by switching to anti-C5 therapy.Moreover, these findings highlight the importance of considering the potential risk associated with treatment discontinuation-including lack of availability, planning or incidental occurrence of pregnancy- before initiating therapy with proximal complement inhibitors.While not the primary focus, this report highlights the intricacies of modern clin. research, where industrial considerations can sometimes hinder the development of potentially beneficial treatments or compromise patient safety.It also emphasizes the responsibilities of academic investigators in providing strong guidance in the design of clin. trials, avoiding that lack of expertise or industrial interests could compromise science and patient safety.

2023-12-04·Clinical kidney journal

Targeting complement in IgA nephropathy

Review

作者: Gutiérrez, Eduardo ; Caravaca-Fontán, Fernando ; Sevillano, Ángel M ; Praga, Manuel

ABSTRACT:

Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Recent years have witnessed significant improvements in the understanding of the pathogenesis of IgAN and particularly, the pathogenic role of complement activation. The alternative complement pathway is the major complement cascade activator in IgAN, and glomerular C3 deposition has been shown to correlate with disease progression. In addition, several studies have provided insight into the pathogenic role of factor H–related proteins -1 and -5 in IgAN, as independent players in complement dysregulation. The lectin pathway has also been shown to be associated with the severity of IgAN. Glomerular deposition of C4d has been associated with increased histologic disease activity, faster decline in estimated glomerular filtration rate and higher risk of kidney failure. On the other hand, although overlooked in the Oxford classification, numerous studies have shown that the coexistence of thrombotic microangiopathy in IgAN is a significant indicator of a poorer prognosis. All the breakthroughs in the understanding of the contributing role of complement in IgAN have paved the way for the development of new complement-targeted therapies in this disease. Several ongoing trials are evaluating the efficacy of new agents against factor B (iptacopan, Ionis-FB-LRX), C3 (pegcetacoplan), factor D (vemircopan, pelecopan), C5 (ravulizumab, cemdisiran) and C5a receptor 1 (avacopan). In this study, we provide a comprehensive review of the role of complement in IgAN, including the emerging mechanisms of complement activation and the promising potential of complement inhibitors as a viable treatment option for IgAN.

项与维米克泮相关的新闻（医药）

2025-02-06

·EndPoints

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for Alexion in 2021. The UK major recorded an impairment charge of $753 million as a result, according to 2024 earnings that were reported on Thursday. Development of vemircopan for paroxysmal nocturnal hemoglobinuria was halted in November 2023, but now the drug is being abandoned completely. A Phase 2 trial in lupus nephritis or IgA nephropathy, and an early-stage trial in impaired hepatic function, have also been discontinued for lack of efficacy. Marc Dunoyer, the CEO of AstraZeneca’s rare disease unit, said it “is not immune to the odds of the industry, where not all of the pioneering work that you do is going to work.” He added that the decision to drop vemircopan was based on standard criteria, namely its benefits and risks, as well as the competitive situation. Despite the loss, AstraZeneca CEO Pascal Soriot told reporters at a London event: “I can say with no hesitation, the Alexion acquisition was a fantastic acquisition.” AstraZeneca also took a $165 million impairment on FPI-2059, a Phase 1-stage radioligand that was scrapped. The drug was part of last year’s purchase of Fusion Pharmaceuticals. FPI-2059 is a lutetium-labeled small molecule targeting neurotensin receptor 1 which Alexion itself licensed from Ipsen in 2021. Other radioligands remain in development. AstraZeneca’s lead radioconjugate, FPI-2265, is a beta-emitting, PSMA-targeting product. Data on its Phase 2 prostate cancer trial could come in the second half of this year. “The field of radioconjugates is a little behind the field of ADCs at the moment, but it holds great potential,” AstraZeneca’s oncology R&D leader Susan Galbraith said at the earnings event. Elsewhere, AstraZeneca shut down: The company also reiterated the termination of a mid-stage study of an orexin 1 receptor antagonist, AZD4041, in opioid use disorder. The shuttering emerged in November , with a spokesperson telling Endpoints News the move was due to “a potential drug-drug interaction.” It appears that AstraZeneca will put its long-acting amylin asset AZD6234 into a new Phase 2b trial in obesity, in combination with the GLP-1/glucagon agonist AZD9550. According to a record on the EU’s trial database , the trial will end in the middle of next year. AZD6234 is already in a separate mid-stage monotherapy trial, which could yield data late this year. The company claimed it is heading into an “unprecedented catalyst-rich 2025,” citing a handful of late-stage trials for indication expansions, such as the AVANZAR study of Datroway in first-line non-small cell lung cancer. David Fredrickson, the leader of the company’s oncology business, affirmed his confidence in the ADC despite its stumbles in late-stage trials in both lung and breast cancers. “We’ve been able to apply the lessons that we’ve learned from the previous Phase 3 and Phase 2 studies that have read out so far to the frontline AVANZAR study,” Fredrickson said. The trial is enriched for the non-squamous population “because we think that’s the opportunity to see the most benefit for Datroway in the front line.” Combining the drug with the checkpoint inhibitor Imfinzi could also increase the chances of success, he said. Other major Phase 3 readouts will come for products still in earlier stages, such as the SERD camizestrant in breast cancer, baxdrostat in hypertension, and eneboparatide in hypoparathyroidism.

临床1期临床2期并购临床3期

2024-05-13

·BiG生物创新社

占比43% ，“孤儿”已不孤：辉瑞、阿斯利康、强生、诺华如何布局罕见病？

作者｜自由译员Isabelle4月27日，FDA批准Beqvez（fidanacogene elaparvovec-dzkt）用于治疗成人出血性疾病B型血友病。这是辉瑞首个获得FDA批准的基因疗法，也是该适应症继CSL和uniQure的治疗药物Hemgenix后的第二款药物。Hemgenix于2022年获批，以350万美元的单价荣膺彼时全球最贵药物的称号。辉瑞本有机会使Beqvez的定价低于Hemgenix，但最终决定保持350万美元的单价。然而350万的价格已经并非全球最贵药物了——3月，协和麒麟和Orchard Therapeutics研发的基因疗法Lenmeldy上市，用于治疗罕见遗传病异染性脑白质营养不良，以425万美元的标价晋身天价药之王。关于Beqvez的定价，辉瑞表示，“考虑到潜在的长期收益可以抵消当今慢性病的治疗成本，Beqvez可以为卫生系统节约费用，所提价值主张令人信服。 ”2014年，辉瑞开启基因疗法项目，向Spark支付了2,000万美元预付款和2.6亿美元潜在里程碑付款。根据协议，Spark负责一期和二期开发，然后由辉瑞接手。但FDA并非第一个批准Beqvez的机构。1月，加拿大批准将Beqvez应用于基于腺相关病毒（AAV）载体的治疗。这两次批准都许可将Beqvez用于治疗中度至重度B型血友病患者，且这些患者对变异腺相关病毒（AAV）血清型Rh74的中和抗体呈阴性。B型血友病是一种罕见遗传病，患者无法生成凝血因子IX（FIX）的蛋白质，血液无法正常凝固。据世界血友病联盟称，全球患病人数不过38,000人。罕见病是辉瑞六大重点领域之一（其余五个分别是内科、炎症与免疫、疫苗、肿瘤、抗感染），目前辉瑞尚有8款罕见病管线，分别是：a.治疗杜氏肌营养不良的fordadistrogene movaparvovec，处于临床试验二期；b.治疗2-3岁男童杜氏肌营养不良的fordadistrogene movaparvovec，处于临床试验三期；5月1日更新的辉瑞管线c.治疗A型和B型血友病的marstacimab，目前已至注册阶段；d.治疗A型血友病的giroctocogene fitelparvovec，目前处于临床试验三期：e.治疗成人生长激素缺乏症的NGENLATM，目前处于临床试验三期：f.治疗镰刀型细胞贫血症的inclacumab和►osivelotor，目前处于临床试验三期；g.治疗小儿镰刀型细胞贫血症的Oxbryta®，目前处于临床试验三期。 5月1日更新的辉瑞管线 01 阿斯利康：市场药荒，并购正当时3月，阿斯利康购买了法国药企Amolyt Pharma，以获得eneboparatide，这是一种治疗甲状旁腺功能减退的药物，目前处于临床试验三期。甲状旁腺功能减退症是指甲状旁腺不能分泌足够的甲状旁腺激素。这种激素对调节血液中的钙和磷酸盐水平很重要。该病对女性的影响尤其严重。可以通过补充钙和维生素D治疗，但大剂量补充钙可能会引起便秘等肠胃问题。Amolyt提供的治疗方法有所不同，eneboparatide是一种靶向绑定在甲状旁腺激素1型受体上的肽药，天然的甲状旁腺激素也是绑定在这一受体上的。Amolyt表示，该药可能无需每日补充钙和维生素D即可使血钙水平恢复正常，且可以保持骨密度，这对于有较高风险出现骨质疏松症等骨骼问题的病人很重要。Amolyt称最迟今年底可获得初步的三期数据。阿斯利康此次出手时机恰到好处，因为唯一已获得FDA批准的药物停产在即，市场正亟需一款甲状旁腺功能减退症新药。武田的Natpara自2015年获得FDA批准后，商业化之路一直坎坷。2019年，由于Natpara药筒产生的橡胶微粒可能污染注射药品，FDA要求武田召回Natpara。随后三年，武田一直试图重新上市Natpara，但都遭到了FDA的拒绝。2022年，武田表示，计划最迟于2024年停产Natpara。阿斯利康计划于三季度完成对Amolyt的收购，Amolyt将并入阿斯利康的罕见病分部Alexion。目前阿斯利康自身有18款罕见病管线，包括：● 7个LCM（全生命周期管理）项目：a 治疗地图样萎缩的danicopan；b 治疗造血干细胞移植相关血栓性微血管病、全身性重症肌无力、增殖性狼疮性肾炎、免疫球蛋白A（IgA）型肾病的Ultomiris；c 治疗心脏手术相关急性肾损伤的Ultomiris ARTEMIS；d 治疗视神经脊髓炎谱系疾病的Ultomiris CHAMPION-NMOSD。● 6个三期临床试验项目：a 治疗转甲状腺素蛋白淀粉样变性心肌病的acoramidis和ALXN2220；b 治疗淀粉样蛋白轻链淀粉样变性的anselamimab；c 治疗碱性磷酸酶过少的efzimfotase alfa；d 治疗全身性重症肌无力的gefurulimab；e 治疗阵发性夜间血红蛋白尿合并临床显著血管外溶血的Voydeya ALPHA。● 1个二期临床试验项目：治疗增殖性狼疮性肾炎或IgA型肾病的vemircopan。● 4 个一期临床试验项目：a 改善骨代谢的ALXN1910；b 治疗肾病的ALXN1920和ALXN2030；c 口服补体因子D抑制剂Mechanism。 02 强生：双药告捷，喜提重症肌无力突破疗法2月，强生公司宣布，旗下抗体疗法nipocalimab在全身型重症肌无力（gMG）关键的三期研究和干燥综合征（SjD）二期研究获得积极顶线成果。Nipocalimab可以阻断特定受体，阻止免疫系统攻击患者的健康细胞。目前，对于SjD，全球尚没有获批的疗法。自身免疫性疾病是指免疫球蛋白G（IgG）抗体攻击身体，引起疾病。在重症肌无力中，抗体攻击乙酰胆碱受体。在胎儿新生儿溶血病（HDFN）中，抗体攻击婴儿的红细胞。Nipocalimab可以绑定受体，使抗体无法被重新使用，从而减少抗体数量。重点是，Nipocalimab可以防止抗体穿过胎盘。所以，有可能仅靠一种疗法就能将致病性IgG抗体引起的所有疾病一网打尽。这些疾病可分为三大类：由致病性自身抗体引起的疾病、自身抗体影响妊娠的疾病、自身抗体引起的常见风湿病。强生称，有了nipocalimab，自己是唯一一家药物开发覆盖这三类疾病的公司。强生目前尚在开发nipocalimab用于治疗胎儿新生儿溶血病和特发性炎性肌病的管线。 03 诺华：首款口服，潜在重磅疗法获批去年12月，FDA批准了诺华的一款口服新药Fabhalta，用于治疗一种罕见且严重的血液病，称为阵发性睡眠性血红蛋白尿症（PNH）。 PNH是由补体系统（免疫系统的一部分）失调引起的，特征是补体系统会过早破坏红细胞，“溶血”会造成贫血、血栓等症状。针对PNH患者进行的临床研究证实Fabhalta有助于提高患者的血红蛋白水平。诺华期望Fabhalta未来十年可以成为重要的业务支柱。公司相信随着Fabhalta的使用扩展至其他补体系统相关疾病，如IgA肾病和C3肾小球病，年销售额最终可高达30亿美元。诺华进行了两次后期试验，分别招募的是接受过和未接受过C5抑制剂（另一种PNH药物）治疗的患者。第一次试验中，在无需输血的前提下，82%服用Fabhalta的受试者每分升血红蛋白稳定增加了2克以上，相比之下，继续用C5抑制剂治疗的患者血红蛋白没有增加。第二次试验的相关数据为78%。基于这两次试验的结果，FDA批准了Fabhalta。目前诺华还有8款罕见病管线，分别是：a.治疗脊髓性肌萎缩症的AVXS-101；b.治疗IgA肾病（此病在欧美算罕见病，在亚洲不算）的EXV811和FUB523；c.治疗C3肾小球病和非典型溶血性尿毒症的Fabhalta；d.治疗胃肠胰腺神经内分泌肿瘤的Lutathera；e.治疗淋巴管畸形的Vijoice；f.治疗多发性硬化的LOU064。以上项目均进行到三期临床试验。写在最后罕见病，又称“孤儿病”，世界卫生组织的定义是患病人数占总人口的0.65‰～1‰的疾病，我国的定义是新生儿发病率小于1/万、患病率小于1/万、患病人数小于14万的疾病。尽管每种病的患病人数少，但是罕见病种类繁多，全球确认的罕见病有7000多种，总患病人数有3亿。这是一个不可忽视、也不应该被忽视的群体。但现实是其中大部分病无药可治。企业研发罕见病药物，有两个绕不过去的困难：投入产出比和寻找足够的受试者。一方面每种疾病受众基数小，另一方面药物研发需要投入的成本一样不少，所以算经济账，企业研发罕见病并不合算，这也是为什么天价药王多出自罕见病药的原因。同时，也是因为受众基数小，企业需要费更多的周折才能找到足够的受试者。但是，尽管有这两重困难，上世纪八十年代末，只有5%的新药是罕见病药，而去年，这个数字已经上升到43%，大型药企的管线中都有罕见病药的身影，“孤儿病”正得到越来越多的重视。相信随着政策扶持、技术进步，会有越来越多的人负担得起治疗。毕竟，任何药物，都不应该是富人的专属；毕竟，我们生来平等，而生命，本无价。参考资料：Fierce Pharma: Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per doseMedCity News: AstraZeneca Acquisition Brings Drug to Fill a Rare Disease Gap Left by TakedaBiophara Dive: Novartis gets FDA approval of closely watched rare disease drugPharmaVoice: J&J’s growing rare disease focus brings a potential multi-use treatment to the table辉瑞、阿斯利康、强生、诺华、Fabhalta官网 BiG 十周年预告本次BiG十周年庆典，将首次分为国内和国际篇章，以原创科学和临床需求为出发点，讨论创新技术平台和创新疗法（PROTACT/分子胶、双抗/ADC、siRNA/ASO、CGT、AI制药）的重大进展和发展前景，十年一药曙光现，大浪淘沙始见金！▼报名参会会议门票：审核制(免费)；含主论坛+分论坛，不含餐；优先biotech/Pharma、临床、院校科学家共建Biomedical创新生态圈！如何加入BiG会员？

临床2期临床3期孤儿药基因疗法引进/卖出

2024-05-10

·药精通Bio

阿斯利康Q1终止了哪些项目

深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，7月相约苏州，联系电话181 1603 6798上周四阿斯利康（AZ）发布2024年一季度报。在研发管线部分，AZ移除了3个新分子管线项目和1个项目的适应症开发。AZ的首席财务官 Aradhana Sarin 在媒体会议上讨论了终止情况，并解释说该行动是基于公司的“内部评估”，并且“只是我们正常优先级流程的一部分”。AZD5055：procupine抑制剂，用于特发性肺纤维化，本次调整从1期阶段项目移除，即AZ放弃了该项目的开发。本项目由AZ于2020年8月以1700万美元首付、3.6亿美元的潜在里程碑从Redx Pharma引进。Porcupine属于wnt通路的关键酶，wnt信号通路常常和损伤修复相关。理论上，针对procupine可以解决肺部疤痕问题。为了检验这一理论，AZ在 2021 年至 2023 年间进行了四项一期临床试验。AZ没有公开透露其在研究中了解到的情况，但认为已经看到足够的情况，并从其管道中取消了该项目。AZD7503（ION455）：羟基类固醇17-β脱氢酶13 (HSD17B13)的反义寡核苷酸药物，潜在的代谢功能障碍相关脂肪性肝炎 (MASH)疗法。2018年AZ支付3000万美元与Ionis达成合作共同开发。AZ对该分子进行了一系列早期试验，最终于 2023 年在MASH中启动了一项研究。编码 HSD17B13 蛋白的基因的遗传变化与 MASH 的发生和严重程度相关，但AZ已决定放弃该分子的开发。MEDI6570：阻断 LOX-1 清道夫受体配体的抗体， 2020 年AZ将该分子纳入 2 期试验，以评估它是否可以改善有心脏病史的患者的预后。这项研究于去年 11 月完成，而此次调整将该资产从管线中移除。早期的研究表明 LOX-1 参与了动脉斑块形成的所有主要阶段，但临床数据未能让AZ相信该分子的潜力。Vemircopan（维米克泮）：口服d因子抑制剂，作用于旁路途径激活，目前正在全球开展4项临床2期研究和1项1期研究。此次调整终止了该分子用于重症肌无力的试验。阵发性睡眠性血红蛋白尿症、IgA肾病和狼疮性肾炎的2期试验仍在进行中。END深度聚焦多肽、多肽偶联药物研发、质控、工艺开发，7月相约苏州，联系电话18116036798戳“阅读原文”立即报名多肽药物论坛吧!

寡核苷酸临床2期临床终止临床1期引进/卖出

100 项与维米克泮相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重症肌无力	临床2期	美国	Alexion Pharmaceuticals, Inc.	2022-04-27
重症肌无力	临床2期	加拿大	Alexion Pharmaceuticals, Inc.	2022-04-27
重症肌无力	临床2期	德国	Alexion Pharmaceuticals, Inc.	2022-04-27
重症肌无力	临床2期	意大利	Alexion Pharmaceuticals, Inc.	2022-04-27
重症肌无力	临床2期	塞尔维亚	Alexion Pharmaceuticals, Inc.	2022-04-27
重症肌无力	临床2期	西班牙	Alexion Pharmaceuticals, Inc.	2022-04-27
重症肌无力	临床2期	中国台湾	Alexion Pharmaceuticals, Inc.	2022-04-27
免疫球蛋白a肾病	临床2期	美国	Alexion Pharmaceuticals, Inc.	2022-01-14
免疫球蛋白a肾病	临床2期	美国	Catalent CTS, Inc.	2022-01-14
免疫球蛋白a肾病	临床2期	中国	Alexion Pharmaceuticals, Inc.	2022-01-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05097989 (ASN2025)	临床2期	免疫球蛋白a肾病	61	ALXN2050 180mg	憲鹽鹹蓋顧衊淵鏇襯願(醖鬱壓醖鑰構廠醖顧積) = The majority of AEs (IgA nephropathy cohort) during initial evaluation period were mild and not related (Table 2). No serious treatment-related AEs or discontinuations from AEs occurred with ALXN2050. During the extension period, a pt on ALXN2050 180mg had an AE of liver enzyme elevation with positive rechallenge. 網構餘網夢積膚襯膚窪 (鏇壓憲鬱選夢觸醖艱簾 )	不佳	2025-11-07
				ALXN2050 120mg
NCT05097989 (ASN 12025 \| ASN 22025)	临床2期	狼疮性肾炎 \| 免疫球蛋白a肾病	81	Vemircopan	獵積窪壓淵製獵艱鏇構(鹹構餘簾鬱選壓網繭顧) = 醖襯淵廠簾蓋積鑰齋艱衊獵蓋糧糧鑰製鏇網窪 (遞襯壓獵鏇窪選製鑰壓 )	-	2025-10-15
				Vemircopan	獵積窪壓淵製獵艱鏇構(鹹構餘簾鬱選壓網繭顧) = 壓鹽願糧膚築襯鬱廠範衊獵蓋糧糧鑰製鏇網窪 (遞襯壓獵鏇窪選製鑰壓 )
NCT05097989 (CTgov)	临床2期	免疫球蛋白a肾病 \| 狼疮性肾炎	100	ALXN2050 (IgAN Cohort: ALXN2050 120 mg)	遞醖網積齋範製鑰廠選(鹹窪鬱淵醖鹹鏇積繭鹹) = 鹹餘構網衊憲積膚簾糧鹹廠獵襯窪選繭艱構淵 (壓膚衊膚積願網獵繭襯, 衊膚遞網鏇築簾餘構襯 ~ 簾憲壓夢憲廠獵鹹憲糧) 更多	-	2025-10-15
				ALXN2050 (IgAN Cohort: ALXN2050 180 mg)	遞醖網積齋範製鑰廠選(鹹窪鬱淵醖鹹鏇積繭鹹) = 鹽遞壓築膚範鑰鹽衊艱鹹廠獵襯窪選繭艱構淵 (壓膚衊膚積願網獵繭襯, 衊憲顧鑰壓憲鑰選淵簾 ~ 顧範顧鹽簾遞糧範齋鏇) 更多
NCT05218096 (CTgov)	临床2期	重症肌无力	70	ALXN2050 (Group 1: ALXN2050 180 mg BID)	艱繭製糧簾願願齋繭醖 = 夢餘餘範積鏇艱艱願鏇夢憲窪構願簾膚獵鏇鹹 (鬱鹽網窪選糧壓製壓獵, 窪鹽淵襯衊顧夢製網願 ~ 構廠糧廠憲糧餘獵製構) 更多	-	2025-01-09
				ALXN2050 (Group 2: ALXN2050 120 mg BID)	艱繭製糧簾願願齋繭醖 = 獵範積範襯積獵齋蓋鬱夢憲窪構願簾膚獵鏇鹹 (鬱鹽網窪選糧壓製壓獵, 衊衊糧襯簾糧遞淵鏇鹽 ~ 衊餘構窪窪窪窪鏇艱積) 更多
NCT04170023 (CTgov)	临床2期	阵发性睡眠性血红蛋白尿症	29	ALXN2050 (Group 1: Treatment Naive)	積衊鏇簾糧觸範廠遞願(窪齋衊獵壓製鑰餘顧淵) = 廠夢醖蓋製範醖選選醖蓋鏇艱蓋壓夢鹽壓願遞 (積鹽壓鹹蓋網鬱襯鑰積, 14.70) 更多	-	2024-08-09
				Eculizumab (Group 2: Eculizumab Switch)	積衊鏇簾糧觸範廠遞願(窪齋衊獵壓製鑰餘顧淵) = 醖構鹽憲鬱窪觸築廠願蓋鏇艱蓋壓夢鹽壓願遞 (積鹽壓鹹蓋網鬱襯鑰積, 20.03) 更多